Loomis Sayles & Co. L P Acquires 113,818 Shares of Xencor, Inc. (NASDAQ:XNCR)

Loomis Sayles & Co. L P grew its holdings in shares of Xencor, Inc. (NASDAQ:XNCRGet Rating) by 6.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,818,057 shares of the biopharmaceutical company’s stock after purchasing an additional 113,818 shares during the quarter. Loomis Sayles & Co. L P owned about 3.05% of Xencor worth $48,506,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in XNCR. American Century Companies Inc. bought a new position in Xencor during the fourth quarter worth about $201,000. Victory Capital Management Inc. boosted its position in Xencor by 3.8% during the fourth quarter. Victory Capital Management Inc. now owns 23,361 shares of the biopharmaceutical company’s stock worth $937,000 after purchasing an additional 857 shares during the period. First Trust Advisors LP bought a new position in Xencor during the fourth quarter worth about $718,000. Bank of America Corp DE lifted its holdings in shares of Xencor by 98.5% in the fourth quarter. Bank of America Corp DE now owns 92,966 shares of the biopharmaceutical company’s stock worth $3,730,000 after buying an additional 46,133 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Xencor by 5.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 845,227 shares of the biopharmaceutical company’s stock worth $33,912,000 after buying an additional 45,409 shares in the last quarter. Institutional investors own 99.28% of the company’s stock.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $25.32 on Friday. Xencor, Inc. has a one year low of $19.35 and a one year high of $43.61. The firm’s 50 day simple moving average is $29.26 and its two-hundred day simple moving average is $27.13. The stock has a market capitalization of $1.51 billion, a P/E ratio of 74.47 and a beta of 0.62.

Xencor (NASDAQ:XNCRGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). Xencor had a net margin of 7.77% and a return on equity of 3.15%. The business had revenue of $30.18 million for the quarter, compared to the consensus estimate of $34.35 million. As a group, equities analysts expect that Xencor, Inc. will post -1.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on XNCR. Piper Sandler lowered their price target on shares of Xencor from $66.00 to $42.00 and set an “overweight” rating on the stock in a report on Monday, May 23rd. Canaccord Genuity Group reissued a “buy” rating and issued a $50.00 price target on shares of Xencor in a report on Wednesday, July 6th. Finally, StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.83.

Xencor Profile

(Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

See Also

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCRGet Rating).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.